Anand Rathi's research report on Sharda Cropchem
Sharda Cropchem continued to outperform in Q3FY26, aided by healthy, 14% y/y volume growth, positive product-mix and favourable forex and market-share gain in its key regions. Growth momentum was aided by better demand especially in Europe and LatAm along with near complete de-stocking across major regions. We believe the prices have bottomed out and the management is confident of price hike in the nearterm, as the volume would rise with the company expanding its reach, penetrating markets and entering new ones. Further, the management remains very confident of sustaining growth momentum in Q4FY26e and FY27e led by improved demand and pricing scenario.
Outlook
Expecting its revenue/EBITDA/PAT to clock 15/27/34% CAGR over FY25-28e, we retain BUY rating on the stock with a revised TP of Rs1,330 (from Rs1,250 earlier), valuing it at 17x FY28e EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.